An immunoprotective monoclonal antibody to lipopolysaccharide.

Abstract

The ability of antisera against lipopolysaccharide (LPS) raised by immunization with gram-negative bacteria to prevent LPS toxicity and death from gram-negative bacteremia is well established. To demonstrate conclusively that the protective antibody is specific for LPS, we tested an anti-LPS monoclonal antibody (mAb) in three animal models. 7G is an IgG3 mAb directed against an oligosaccharide side chain determinant of LPS from E. coli 0111:B4. This anti-LPS mAb increased the LD50 of 0111:B4 LPS in mice and protected rabbits against the dermal Shwartzman reaction elicited by 0111:B4 LPS. 7G mAb also protected mice against lethal infection with mucin-enhanced E. coli 0111:B4. Pretreatment with 250 micrograms of 7G increased the LD50 by more than 1.5 logs. These studies prove that oligosaccharide side chain-specific antibody to LPS confers protection against LPS toxicity in vivo and against experimental gram-negative infection. In addition, these studies suggest the potential of anti-LPS monoclonal antibody as therapy for gram-negative infection.

• Authors: T N Kirkland, E J Ziegler
• Journal: Journal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 132 Issue 5 Pg. 2590-2 (May 1984) ISSN: 0022-1767 [Print] United States
• PMID: 6201551 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Bacterial
• Antibodies, Monoclonal
• Epitopes
• Lipopolysaccharides

Topics

• Animals
• Antibodies, Bacterial (administration & dosage, physiology)
• Antibodies, Monoclonal (administration & dosage, physiology)
• Epitopes (immunology)
• Escherichia coli Infections (immunology, therapy)
• Lethal Dose 50
• Lipopolysaccharides (immunology, toxicity)
• Mice
• Mice, Inbred BALB C
• Rabbits
• Shwartzman Phenomenon (therapy)